| Name | Valtrate |
|---|---|
| Synonyms |
Butanoic acid, 3-methyl-, (1S,6S,7R,7aS)-4-[(acetyloxy)methyl]-6,7a-dihydrospiro[cyclopenta[c]pyran-7(1H),2'-oxirane]-1,6-diyl ester
(1S,6S,7R,7aS)-4-(Acetoxymethyl)-6,7a-dihydro-1H-spiro[cyclopenta[c]pyran-7,2'-oxirane]-1,6-diyl bis(3-methylbutanoate) tolterodine Baldrisedon (1S-(1a,6a,7b,7aa))-3-Methylbutanoic Acid 4-((Acetyloxy)methyl)-6,7a-dihydrospiro(cyclopenta[c]pyran-7(1H),2'-oxirane)-1,6-diyl Ester (1S,6S,7R,7aS)-4-[(acetyloxy)methyl]-6,7a-dihydro-1H-spiro[cyclopenta[c]pyran-7,2'-oxirane]-1,6-diyl bis(3-methylbutanoate) valepotriate ValtratuM Halazuchrome B ValepotriatuM EINECS 242-174-2 |
| Description | Valepotriate, isolated from Valeriana jatamansi Jones, has anti-epileptic and anti-cancer activities[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | Valepotriate showed significant anti-epileptic activity against MES- and PTZ-induced epilepsy at doses of 5, 10, and 20 mg/kg, and ED50 values for MES- and PTZ-induced epilepsy were 7.84 and 7.19 mg/kg, respectively. Furthermore, valepotriate (10 and 20 mg/kg) can significantly prolong sleeping time and shorten the latency time on the pentobarbital sodium-induced sleeping time test. Furthermore, valepotriate (5, 10, and 20 mg/kg) could significantly up-regulate the expression of GABAA, GAD65, and Bcl-2 and down-regulate the expression of caspase-3, but had no significant effect on the expression of GABAB[2]. |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 525.9±50.0 °C at 760 mmHg |
| Molecular Formula | C22H30O8 |
| Molecular Weight | 422.469 |
| Flash Point | 226.5±30.2 °C |
| Exact Mass | 422.194061 |
| PSA | 100.66000 |
| LogP | 2.36 |
| Vapour Pressure | 0.0±1.4 mmHg at 25°C |
| Index of Refraction | 1.528 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
| HS Code | 29329990 |
|---|
| Precursor 0 | |
|---|---|
| DownStream 1 | |